Clinical features and respiratory mechanics of study population
The flowchart of this study is shown in eFigure 2, Supplementary materials. Over the study period a total of 21 patients with AE-ILD-UIP resulted eligible for enrollment. Of these, 5 patients were analyzed according to inclusion criteria. All of them showed a definite UIP pattern on HRCT scan. Patients were prevalently male (n = 4) with a median age of 62 years (56–68) (eTable 1, Supplementary materials). Two of them were diagnosed with IPF. Among the others, one had rheumatoid arthritis associated ILD, one had chronic hypersensitivity pneumonitis and one presented an undetermined ILD. All patients died as inpatients while on MV. AE-ILD-UIP and matched ARDS groups were similar for clinical severity scores (APACHE and SAPS II, eTable 1, Supplementary materials). All ARDS patients presented a pulmonary ARDS occurring from lung infection.
Respiratory mechanics of AE-ILD-UIP and matched ARDS groups at different PEEP levels are showed in Table 1. The PEEPLOW level was similar, whereas PEEP TITRATED resulted in higher PEEP level in the AE-ILD-UIP group (Table 1).
Table 1
Blood gas analyses and respiratory mechanics of the AE-ILD-UIP and the ARDS population at different PEEP levels. Data are presented as median value and IQR.
Variable | AE-ILD-UIP | ARDS | p-value |
ZEEP phase | | | |
EL, cmH2O/L | 43.2 (39.9–54.4) | 21 (17.3–35.6) | 0.01 |
Ecw, cmH2O/L | 3.3 (2.8–7) | 4.5 (4–6.3) | 0.72 |
Etot, cmH2O/L | 50 (43.8–57.4) | 26.4 (21.6–41.2) | 0.01 |
PL,EI, cmH2O | 16.1 (13.3–18.5) | 7 (4.9–7) | 0.0002 |
PL,EE, cmH2O | -4.3 (-7.7 – -2.9) | -4 (-7.5 – -1.2) | 0.71 |
ΔPaw, cmH2O | 17.5 (16.3–19.3) | 21.2 (17.5–22.8) | 0.13 |
ΔPL, cmH2O | 21.3 (18.1–23.8) | 9.4 (8.9–13.2) | 0.0003 |
EELV, ml | 693 (588–717) | 820 (599–1047) | 0.18 |
Strain, ration | 0.58 (0.49–0.62) | 0.5 (0.39–0.67) | 0.68 |
pH, value | 7.42 (7.39–7.44) | 7.39 (7.37–7.41) | 0.17 |
pO2, cmH2O | 75 (72–80) | 80 (65–90) | 0.73 |
pCO2, cmH2O | 38 (35–41) | 39 (38–42) | 0.35 |
PEEPLOW phase | | | |
EL, cmH2O/L | 44 (38.8–57.8) | 18.3 (15.4–29.5) | 0.003 |
Ecw, cmH2O/L | 3.6 (2.7–7) | 4.3 (4–6.4) | 0.73 |
Etot, cmH2O/L | 52 (42.3–60.9) | 23.6 (19.5–35.3) | 0.005 |
PL,EI, cmH2O | 14 (10.9–18.8) | 12 (8.7–15) | 0.26 |
PL,EE, cmH2O | -2.2 (-6.5 – -1) | -2.1 (-5.4 – -0.6) | 0.78 |
ΔPaw, cmH2O | 18.2 (14.8–18.8) | 20.8 (16.2–26) | 0.18 |
ΔPL, cmH2O | 18.4 (15.6–21.8) | 16.1 (9.3–19.4) | 0.32 |
PEEP, cmH2O | 4 (4–4) | 4 (4–5) | 0.71 |
EELV, ml | 702 (625–762) | 1010 (733–1175) | 0.04 |
Strain, ratio | 0.62 (0.6–0.74) | 0.96 (0.63–1.1) | 0.08 |
pH, value | 7.4 (7.38–7.43) | 7.39 (7.35–7.4) | 0.18 |
pO2, cmH2O | 75 (72–78.5) | 80 (69.5–95.5) | 0.31 |
pCO2, cmH2O | 39 (36–42.5) | 40 (38.5–44) | 0.39 |
PEEPTITRATED phase | | | |
EL, cmH2O/L | 50 (42.8–60.5) | 15.4 (14.4–20.9) | < 0.0001 |
Ecw, cmH2O/L | 3.9 (3.4–7.2) | 4.3 (4–6.5) | 0.97 |
Etot, cmH2O/L | 59 (47.3–64.2) | 21 (18.6–26.6) | < 0.0001 |
PL,EI, cmH2O | 26.2 (19.9–29.8) | 18.2 (16.5–20.3) | 0.03 |
PL,EE, cmH2O | 0.3 (0.3–1.4) | 0.6 (0.1–1) | 0.63 |
ΔPaw, cmH2O | 20 (17.3–21.8) | 16.5 (14–18.4) | 0.06 |
ΔPL, cmH2O | 25 (19–29.5) | 17.6 (15.6–20.2) | 0.04 |
PEEP, cmH2O | 12 (10–14) | 14 (12–17.5) | 0.03 |
EELV, ml | 714 (635–755) | 1260 (912–1575) | 0.01 |
Strain, ratio | 0.69 (0.63–0.83) | 1.8 (1.5–1.9) | < 0.0001 |
pH, value | 7.39 (7.36–7.42) | 7.36 (7.32–7.39) | 0.14 |
pO2, cmH2O | 78 (55–85) | 80 (73–91) | 0.3 |
pCO2, cmH2O | 40 (37–44) | 42 (40–48) | 0.27 |
AE-ILD-UIP, acute exacerbation of interstitial lung disease with usual interstitial pneumonia pattern; ARDS, acute respiratory distress syndrome; IQR, interquartile range; ΔPL, transpulmonary driving pressure; PL,EI, end-inspiratory transpulmonary pressure; PL,EE, end-expiratory transpulmonary pressure; ΔPaw, driving pressure; Etot, respiratory system elastance; Ecw, chest wall elastance; EL, lung elastance; PEEP, positive end-expiratory pressure |
Table 2
shows the fitting results for the elasticity parameters, \({c}_{1}\) and \({c}_{2}\), and the collagen thickness fraction \({\chi }_{2}\) in the shell model. The estimates indicate a range of variation of 53–189 cmH2O (≅5.2–18.5 kPa) for the elastic parameter \({c}_{1}\) of elastin and ground substance, 365–702 cmH2O (about 35.8–68.8 kPa) for the elastic parameter \({c}_{2}\) of collagen.
Data source | Adj-R2 | SSE | Elastin and ground substance | Collagen |
\({\varvec{c}}_{1}\) (cmH2O) | \({\varvec{c}}_{2}\) (cmH2O) | \({\varvec{\chi }}_{2}\) (-) |
Healthy lung (D’Angelo et al.)13 | 0.9774 | 2.458 | 53.29 [39.71–66.87] | 365.0 [246–483.9] | 0.05 [-0.19–0.29] |
Healthy lung (Levy et al.)14 | 0.9754 | 8.07 | 74.64 [66.21–83.06] | 392.9 [315.7–470.0] | 0.04 [-0.07–0.15] |
ARDS | 0.7435 | 135.0 | 95.0 [70.0–120.0] | 212.0 [91.05–333.0] | 0.08 [-0.16–0.32] |
AE-ILD-UIP | 0.5743 | 340.9 | 189.4 [102.1–276.7] | 702.3 [370.7–1034] | 0.31 [-0.01–0.63] |
At ZEEP, AE-ILD-UIP patients had higher EL (43.2 [39.9–54.4] cmH2O/L, p = 0.01), PL,EI (16.1 [13.3–18.5] cmH2O, p = 0.0002) and ΔPL (21.3 [18.1–23.8] cmH2O, p = 0.0003) as compared to ARDS patients (Table 1). Conversely, ΔPaw (17.5 cmH2O/L VS 21.2 cmH2O/L, p = 0.1), PL,EE (-4.3 cmH2O/L VS -4 cmH2O/L, p = 0.7) and EELV (693 ml VS 820 ml, p = 0.18) were not different between the two groups (Table 1). During the PEEPLOW and the PEEPTITRATED phases, AE-ILD-UIP patients had higher EL (44 cmH2O/L VS 18.3 cmH2O/L, p = 0.003 and 50 cmH2O/L VS 15.4 cmH2O/L, p = 0.0001, respectively) and lower EELV (702 ml VS 1010 ml, p = 0.04 and 714 ml VS 1260 ml, p = 0.01, respectively) as compared to ARDS (Table 1). Strain was not different at ZEEP and PEEPLOW between the groups (0.58 VS 0.5 cmH2O/L, p = 0.68 and 0.62 VS 0.96, p = 0.08, respectively), while AE-ILD-UIP patients showed significantly lower strain values during the PEEPTITRATED phases (0.62 VS 1.8, p < 0.0001). Figure 1 illustrates and compares the changes in strain according to incremental PEEP values in the two groups. Whereas AE-ILD-UIP and ARDS patients presented an increase in strain during the PEEPTITRATED phase as compared to both ZEEP and PEEPLOW phases, this resulted significantly higher for the latter group (p = 0.003, Fig. 1).
Specific elastance was significantly higher in AE-ILD-UIP as compared to ARDS (28.9 [24.8–33.2] cmH2O versus 11.4 [11.1–14.5] cmH2O, respectively) (Fig. 2).
Stress/strain curve and model fitting
The stress/strain curve according to Eq. (18) (Supplementary materials) for AE-ILD-UIP and ARDS patients and for healthy subjects13,14 is illustrated in Fig. 3, panel A. None of the AE-ILD-UIP patients reached global strain above 1. Four out 5 patients with AE-ILD-UIP reached levels of strain above 0.5 that corresponded to stress values higher than 12.5 cmH2O, irrespective of the selected PEEP. For ARDS patients and healthy subjects, the highest stress values were reached for strain levels between 1.5 and 2. The partitioned analysis of the secant and tangent modulus of AE-ILD-UIP patients showed that the minimum point was reached for strain value of 0.55 (Fig. 3, panel B) and 0.35 (Fig. 3, panel C) respectively.
Figure 4, panel A shows the isolated contributions of elastin plus ground substance and collagen in the pressure-volume curves. The contribution of elastin was prevalent at lower strains, while the contribution of collagen was significant at higher strains. The curve for collagen showed an upward shift passing from normal to AE-ILD-UIP lungs. The partitioned analysis of the secant and tangent modulus for collagen and elastin of AE-ILD-UIP patients is showed in panel B and panel C, respectively. For strain value > 0.5 the tangent modulus of elastin showed a steep decrease, and the tangent modulus of collagen showed a marked increase. At strain = 0.9 the two moduli resulted 3.8 cmH2O for elastin and 50.0 cmH2O for collagen.
The piecewise distributions of the radial and hoop stress components, \({\sigma }_{r}\) and \({\sigma }_{\theta }\) respectively, in three deformed (inflated) configurations of the alveolus, corresponding to three different values of the relative volume change \(\frac{{\Delta }V}{V}\) is shown in eFigure 3 and eFigure 4, Supplementary materials for AE-ILD-UIP and ARDS patients respectively.